Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
KEYWORDS: prasugrel, clopidogrel, patients, group, coronary, clinical, assessment, assessment group, committee, myocardial, trial, acute, treatment, acute coronary, intervention

(cost per QALY weighing less than 60 kg) 182): ICER (cost per QALY gained) per QALY gained) gained) Core clinical cohort £20,247 £11,796 - STEMI with diabetes £1,805 - £1,640 STEMI without diabetes £6,616 - £6,626 Unstable angina or NSTEMI £3,005 - Dominant with diabetes Unstable angina or NSTEMI £136,888 - £4,667 without diabetes Dominant, less costly and more effective; ICER, incremental cost-effectiveness ratio; NSTEMI, non-ST-segment-elevation myocardial infarction; QALY, quality-adjusted life year; STEMI, ST-segment-elevation myocardial infarction The differences between the cost-effectiveness results submitted during the original appraisal of prasugrel and those in the current appraisal (as shown in table 1) are a result of the different economic models used. In particular, in the current appraisal both the manufacturer and the Assessment Group used the whole licensed population in their models, rather than the typical/median patient profile used in the model for the original appraisal (see sections 4.2.1 and 4.2.11). Also, in the current appraisal the Assessment Group used data from the CAPRIE trial in its long-term model rather than data from TRITON-TIMI 38 (see section 4.2.15). 4.3 Consideration of the evidence The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of prasugrel, having considered evidence on
